Experience

Università degli Studi del Molise

• Italy
• Higher Education
• 200 - 300 Employee

• Ricercatore (RTD-A)

  • Jan 2022 - Present

• Assegnista di Ricerca

  • Jul 2020 - Jan 2022



Mission Therapeutics

• United Kingdom
• Biotechnology Research
• 1 - 100 Employee

• Senior Scientist - Biomarkers

  • Jan 2018 - Jan 2020



Horizon Discovery

• United Kingdom
• Biotechnology Research
• 100 - 200 Employee

• Assay and Screening Scientist

  • Apr 2017 - Dec 2017



Medical Research Council - Laboratory of Molecular Biology

• MRC - Laboratory of Molecular Biology

• Post Doctoral Research Associate (Carrier Development Fellow)

  • Mar 2013 - Mar 2017

  Four-year Postdoc in Michel Goedert's group (Neurobiology division) at the MRC-Laboratory of Molecular Biology in Cambridge (UK). My research to date has been focused on neurodegenerative diseases, such as tauopathies (Alzheimer’s) and synucleinopathies (Parkinson’s) in order to investigate their pathogenic molecular mechanisms and find potential therapeutic targets. During my postdoc, I extended my technical knowledge and expertise to mouse and fly models. I tested different compounds on P301S… Show more Four-year Postdoc in Michel Goedert's group (Neurobiology division) at the MRC-Laboratory of Molecular Biology in Cambridge (UK). My research to date has been focused on neurodegenerative diseases, such as tauopathies (Alzheimer’s) and synucleinopathies (Parkinson’s) in order to investigate their pathogenic molecular mechanisms and find potential therapeutic targets. During my postdoc, I extended my technical knowledge and expertise to mouse and fly models. I tested different compounds on P301S tau mouse models in order to investigate their potential therapeutic effect on tau pathology, as well as I investigated passive immunization with anti-tau p-S422 antibody. Starting from scratch, but motivated by my curiosity, my challenging spirit and self-motivation, I generated my own tau Drosophila lines, introducing this model into the lab. I successfully carried out a Drosophila project identifying a possible therapeutic target for inhibiting tau aggregation and therefore neurodegeneration. An internal collaboration has been focused on the understanding of α-synuclein spreading in A53T mouse model of human synucleinopathy; in this context the development of an assay to quantify the amount of aggregated α-synuclein in human and mouse tissues has allowed to correlate the amount of aggregated α-synuclein with the severity of the pathology. Show less Four-year Postdoc in Michel Goedert's group (Neurobiology division) at the MRC-Laboratory of Molecular Biology in Cambridge (UK). My research to date has been focused on neurodegenerative diseases, such as tauopathies (Alzheimer’s) and synucleinopathies (Parkinson’s) in order to investigate their pathogenic molecular mechanisms and find potential therapeutic targets. During my postdoc, I extended my technical knowledge and expertise to mouse and fly models. I tested different compounds on P301S… Show more Four-year Postdoc in Michel Goedert's group (Neurobiology division) at the MRC-Laboratory of Molecular Biology in Cambridge (UK). My research to date has been focused on neurodegenerative diseases, such as tauopathies (Alzheimer’s) and synucleinopathies (Parkinson’s) in order to investigate their pathogenic molecular mechanisms and find potential therapeutic targets. During my postdoc, I extended my technical knowledge and expertise to mouse and fly models. I tested different compounds on P301S tau mouse models in order to investigate their potential therapeutic effect on tau pathology, as well as I investigated passive immunization with anti-tau p-S422 antibody. Starting from scratch, but motivated by my curiosity, my challenging spirit and self-motivation, I generated my own tau Drosophila lines, introducing this model into the lab. I successfully carried out a Drosophila project identifying a possible therapeutic target for inhibiting tau aggregation and therefore neurodegeneration. An internal collaboration has been focused on the understanding of α-synuclein spreading in A53T mouse model of human synucleinopathy; in this context the development of an assay to quantify the amount of aggregated α-synuclein in human and mouse tissues has allowed to correlate the amount of aggregated α-synuclein with the severity of the pathology. Show less